Skip to content

CSL BEHRING

Active
Public limited companyfounded 1995active for 31 yearsBedrijvenlaan 11, 2800 Mechelen, BelgiumKBO/BCE: BE 0454.483.701
Summary

CSL BEHRING has been active since 1995 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €48.3m and a net result of €9.0m. Equity is growing by about 21% per year across the filed financial years. Its solvency ranks better than 58% of 6,141 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
10th largest company by equity in Mechelen, Wholesale and retail trade sector1 site
Size
€184.4mturnover 2025
Staff
36.4 FTE
Equity
€48.3m
Profit
€9.0m
Financial health
95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Parent
CSL Behring ApS · 51.83%
Holdings
1
Auditor: DELOITTE Bedrijfsrevisoren BV2025 accounts 43 days early2 of 18 deeds summarised
Why 95raises riskLiquidity: current ratio 2.05lowers riskFounded in 1995Size: turnover €184.4m, 36.4 FTE, total assets €92.0mEquity €48.3m (52.4% of total assets)Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 69% of its sector peers (NACE 46, small)
Financial strength · tick = 2024
Strong
Solvency 77+3
equity 52.4% of total assets
Liquidity 53+4
short-term debt 47.6%
Profitability 69+2
return on assets 9.8%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,374 companies, NACE 46, small)
Last 24 months 11-2024: 0.1% 12-2024: 0.2%▲ +0.1 percentage points vs 11-2024highest value 01-2025: 0.1%▼ -0.1 percentage points vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026lowest value 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €4,550,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.05, compared with 1.92 in 2024, above the usual 1.5; short-term debt: 47.6% of total assets), and 47.6% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 61% on solvency, 70% on liquidity, 60% on profitability and 85% on growth.

The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 2.05
NBB · annual accounts
lowers risk · Founded in 1995
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Size: turnover €184.4m, 36.4 FTE, total assets €92.0m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
lowers risk · Equity €48.3m (52.4% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 19-12-2025, 43 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
43 days early
2024
44 days early
2023
72 days early
2022
47 days early
2021
42 days early
2020
44 days early
2019
35 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 47 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 18 December (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
30-06-2026 year end27-10-2026 today31-01-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Resignation: Marcelo Estrella (director)Appointment: Alexandros Sigalas (director) ·…
  2. Annual accounts filedfinancial year 2025 · full…
  3. Highest result from 2020 to 2025net €9.0m ▲37.7%

Financials · financial year 2025, full format

Turnover
€184.4m▲ 16.1%
2024 · €158.9m
EBIT margin
6.6%▲ 1.1pp
2024 · 5.5%
Net result
€9.0m▲ 37.7%
2024 · €6.5m
Working capital
€45.9m▲ 24.5%
2024 · €36.9m
Trend over the years

2020 to 2025, 5 financial years 2020 to 2025, 5 financial years

After the dip in 2023 the operating result has climbed two years in a row; 2025 is 40% above 2024 and is the highest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Turnover€184.4m 2025 Operating result€12.2m 2025 Net result€9.0m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line20202022202320242025
Turnover€124.6m-€120.6m-€140.9m▲ 16.8%€158.9m▲ 12.8%€184.4m▲ 16.1%
Operating result€6.0m-€6.7m-€6.4m▼ 4.5%€8.7m▲ 36.3%€12.2m▲ 39.7%
Net result€4.1mabove the sector's middle half-€5.0mabove the sector's middle half-€4.5mabove the sector's middle half▼ 10.8%€6.5mabove the sector's middle half▲ 46.2%€9.0mabove the sector's middle half▲ 37.7%
EBIT margin4.8%-5.6%-4.5%▼ 1.0pp5.5%▲ 0.9pp6.6%▲ 1.1pp
Equity€18.5mabove the sector's middle half-€28.3mabove the sector's middle half-€32.7mabove the sector's middle half▲ 15.8%€39.3mabove the sector's middle half▲ 20.0%€48.3mabove the sector's middle half▲ 22.9%
Total assets€48.3mabove the sector's middle half-€46.0mabove the sector's middle half-€64.4mabove the sector's middle half▲ 40.1%€79.4mabove the sector's middle half▲ 23.3%€92.0mabove the sector's middle half▲ 15.9%
Debt€29.8m-€17.7m-€31.7m▲ 78.8%€40.1m▲ 26.7%€43.8m▲ 9.1%
Working capital€15.9mabove the sector's middle half-€25.8mabove the sector's middle half-€30.3mabove the sector's middle half▲ 17.4%€36.9mabove the sector's middle half▲ 21.7%€45.9mabove the sector's middle half▲ 24.5%
Solvency38.2%within the sector's middle half-61.5%within the sector's middle half-50.8%within the sector's middle half▼ 10.7pp49.5%within the sector's middle half▼ 1.4pp52.4%within the sector's middle half▲ 3.0pp
Current ratio1.53within the sector's middle half-2.46within the sector's middle half-1.96within the sector's middle half▼ 0.501.92within the sector's middle half▼ 0.042.05within the sector's middle half▲ 0.13
Return on assets (ROA)8.5%within the sector's middle half-10.9%above the sector's middle half-6.9%within the sector's middle half▼ 4.0pp8.2%within the sector's middle half▲ 1.3pp9.8%above the sector's middle half▲ 1.5pp
Staff (FTE)30.3above the sector's middle half-31.5above the sector's middle half-33above the sector's middle half▲ 4.8%35.9above the sector's middle half▲ 8.8%36.4above the sector's middle half▲ 1.4%
above within below the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €92.0m
Fixed assets €2.4m ▼ 0.7%
Current assets €89.6m ▲ 16.4%
Equity and liabilities €92.0m
Equity €48.3m ▲ 22.9%
Debt €43.8m ▲ 9.1%
Debt's share of the balance-sheet total falls from 50.5% to 47.6%. Equity and debt are higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€12.2m▲
2024 · €8.7m
Cash flow
€9.0m▲
2024 · €6.6m
Quick ratio
1.22▼
2024 · 1.25
Debt to equity
0.91▼
2024 · 1.02
ROE
18.6%▲
2024 · 16.6%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€43.8m▲
2024 · €40.1m
Income taxes
€3.2m▲
2024 · €2.3m
Staff costs
€7.8m▲
2024 · €7.0m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 20,136 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95.0% are still going.

  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
0.2% went bankrupt
4.7% stopped otherwise
95.0% still going

For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 20,136 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 61 lines
Balance sheet Code20242025
Assets
Total assets20/58€79.4m€92.0m▲
Fixed assets21/28€2.4m€2.4m▼
Tangible fixed assets22/27€0.07m€0.06m▼
Furniture and vehicles24€0.03m€0.03m▼
Other tangible fixed assets26€0.04m€0.03m▼
Financial fixed assets28€2.3m€2.3m=
Affiliated companies280/1€2.3m€2.3m=
Participating interests280€2.3m€2.3m=
Current assets29/58€77.0m€89.6m▲
Stocks and contracts in progress3€27.0m€36.4m▲
Stocks30/36€27.0m€36.4m▲
Goods purchased for resale34€27.0m€36.4m▲
Amounts receivable within one year40/41€49.9m€53.1m▲
Trade receivables40€41.8m€45.7m▲
Other amounts receivable41€8.1m€7.4m▼
Deferred charges and accrued income490/1€0.04m€0.06m▲
Equity and liabilities
Total equity and liabilities10/49€79.4m€92.0m▲
Equity10/15€39.3m€48.3m▲
Contributions10/11€1.7m€1.7m=
Capital10€1.7m€1.7m=
Issued capital100€1.7m€1.7m=
Reserves13€0.2m€0.2m=
Non-distributable reserves130/1€0.2m€0.2m=
Legal reserve130€0.2m€0.2m=
Other1319€16€16=
Tax-exempt reserves132€0.04m€0.04m=
Profit (loss) carried forward14€37.4m€46.4m▲
Amounts payable17/49€40.1m€43.8m▲
Amounts payable within one year42/48€40.1m€43.8m▲
Trade debts44€33.7m€40.5m▲
Suppliers440/4€33.7m€40.5m▲
Taxes, remuneration and social security45€6.5m€3.3m▼
Taxes450/3€4.5m€1.0m▼
Remuneration and social security454/9€2.0m€2.3m▲
Income statement Code20242025
Operating income70/76A€162.4m€191.9m▲
Turnover70€158.9m€184.4m▲
Other operating income74€3.5m€7.5m▲
Operating charges60/66A€153.7m€179.8m▲
Goods for resale, raw materials and consumables60€139.7m€166.7m▲
Purchases600/8€138.6m€176.2m▲
Change in stocks: decrease (increase)609€1.1m-€9.4m▼
Services and other goods61€5.3m€5.2m▼
Remuneration, social security and pensions62€7.0m€7.8m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.03m€0.02m▼
Other operating charges640/8€1.8m€160▼
Operating profit (loss)9901€8.7m€12.2m▲
Financial income75/76B€0.2m€0.2m▲
Recurring financial income75€0.2m€0.2m▲
Other financial income752/9€0.2m€0.2m▲
Financial charges65/66B€0.07m€0.2m▲
Recurring financial charges65€0.07m€0.2m▲
Debt charges650€0.05m€0.06m▲
Other financial charges652/9€0.02m€0.2m▲
Profit (loss) for the period before taxes9903€8.9m€12.2m▲
Income taxes67/77€2.3m€3.2m▲
Taxes670/3€2.3m€3.2m▲
Profit (loss) for the period9904€6.5m€9.0m▲
Profit (loss) for the period to be appropriated9905€6.5m€9.0m▲
Appropriation of the result
Profit (loss) to be appropriated9906€37.4m€46.4m▲
Profit (loss) brought forward from the previous period14P€30.9m€37.4m▲
Social balance sheet
Average headcount (FTE)908735.936.4▲

The notes to these accounts (36 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20202022202320242025Change
Operating income70/76A-€123.0m€144.0m€162.4m€191.9m▲ 18.2%
Turnover70€124.6m€120.6m€140.9m€158.9m€184.4m▲ 16.1%
Other operating income74-€2.3m€3.1m€3.5m€7.5m▲ 111%
Operating charges60/66A-€116.3m€137.6m€153.7m€179.8m▲ 16.9%
Goods for resale, raw materials and consumables60-€106.8m€122.2m€139.7m€166.7m▲ 19.4%
Purchases600/8-€107.4m€128.9m€138.6m€176.2m▲ 27.1%
Change in stocks: decrease (increase)609--€0.6m-€6.7m€1.1m-€9.4m-
Services and other goods61-€4.1m€5.4m€5.3m€5.2m▼ 1.2%
Remuneration, social security and pensions62-€5.2m€6.6m€7.0m€7.8m▲ 11.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.06m€0.05m€0.04m€0.03m€0.02m▼ 19.9%
Other operating charges640/8-€0.001m€3.3m€1.8m€160▼ 100.0%
Operating profit (loss)9901€6.0m€6.7m€6.4m€8.7m€12.2m▲ 39.7%
Financial income75/76B-€0.05m€0.006m€0.2m€0.2m▲ 11.0%
Recurring financial income75-€0.05m€0.006m€0.2m€0.2m▲ 11.0%
Other financial income752/9-€0.05m€0.006m€0.2m€0.2m▲ 11.0%
Financial charges65/66B-€0.07m€0.1m€0.07m€0.2m▲ 240%
Recurring financial charges65€0.1m€0.07m€0.1m€0.07m€0.2m▲ 240%
Debt charges650€0.05m€0.05m€0.07m€0.05m€0.06m▲ 17.1%
Other financial charges652/9-€0.01m€0.03m€0.02m€0.2m▲ 898%
Profit (loss) for the period before taxes9903€5.9m€6.7m€6.3m€8.9m€12.2m▲ 37.4%
Income taxes67/77€1.8m€1.7m€1.8m€2.3m€3.2m▲ 36.8%
Taxes670/3-€1.7m€1.8m€2.3m€3.2m▲ 36.8%
Tax adjustments and reversals of tax provisions77-€0.08m----
Profit (loss) for the period9904€4.1m€5.0m€4.5m€6.5m€9.0m▲ 37.7%
Profit (loss) for the period to be appropriated9905€4.1m€5.0m€4.5m€6.5m€9.0m▲ 37.7%
Line20202022202320242025Change
Assets
Total assets20/58€48.3m€46.0m€64.4m€79.4m€92.0m▲ 15.9%
Fixed assets21/28€2.5m€2.4m€2.4m€2.4m€2.4m▼ 0.7%
Tangible fixed assets22/27€0.2m€0.1m€0.1m€0.07m€0.06m▼ 21.1%
Furniture and vehicles24-€0.04m€0.04m€0.03m€0.03m▼ 15.2%
Other tangible fixed assets26-€0.07m€0.06m€0.04m€0.03m▼ 25.0%
Financial fixed assets28€2.3m€2.3m€2.3m€2.3m€2.3m=
Affiliated companies280/1-€2.3m€2.3m€2.3m€2.3m=
Participating interests280-€2.3m€2.3m€2.3m€2.3m=
Current assets29/58€45.8m€43.5m€62.0m€77.0m€89.6m▲ 16.4%
Stocks and contracts in progress3€17.6m€21.4m€28.1m€27.0m€36.4m▲ 34.9%
Stocks30/36-€21.4m€28.1m€27.0m€36.4m▲ 34.9%
Goods purchased for resale34-€21.4m€28.1m€27.0m€36.4m▲ 34.9%
Amounts receivable within one year40/41€28.1m€21.9m€33.5m€49.9m€53.1m▲ 6.4%
Trade receivables40-€21.4m€33.0m€41.8m€45.7m▲ 9.2%
Other amounts receivable41-€0.5m€0.5m€8.1m€7.4m▼ 8.0%
Deferred charges and accrued income490/1-€0.2m€0.3m€0.04m€0.06m▲ 76.9%
Equity and liabilities
Total equity and liabilities10/49€48.3m€46.0m€64.4m€79.4m€92.0m▲ 15.9%
Equity10/15€18.5m€28.3m€32.7m€39.3m€48.3m▲ 22.9%
Contributions10/11€1.7m€1.7m€1.7m€1.7m€1.7m=
Capital10-€1.7m€1.7m€1.7m€1.7m=
Issued capital100-€1.7m€1.7m€1.7m€1.7m=
Reserves13€0.2m€0.2m€0.2m€0.2m€0.2m=
Non-distributable reserves130/1-€0.2m€0.2m€0.2m€0.2m=
Legal reserve130-€0.2m€0.2m€0.2m€0.2m=
Other1319-€16€16€16€16=
Tax-exempt reserves132-€0.04m€0.04m€0.04m€0.04m=
Profit (loss) carried forward14€16.6m€26.4m€30.9m€37.4m€46.4m▲ 24.1%
Amounts payable17/49€29.8m€17.7m€31.7m€40.1m€43.8m▲ 9.1%
Amounts payable within one year42/48€29.8m€17.7m€31.7m€40.1m€43.8m▲ 9.1%
Financial debts43-€4.4m€6.5m---
Other loans439-€4.4m€6.5m---
Trade debts44€22.3m€11.7m€20.6m€33.7m€40.5m▲ 20.3%
Suppliers440/4-€11.7m€20.6m€33.7m€40.5m▲ 20.3%
Taxes, remuneration and social security45-€1.6m€4.6m€6.5m€3.3m▼ 49.4%
Taxes450/3-€0.05m€2.7m€4.5m€1.0m▼ 78.2%
Remuneration and social security454/9-€1.6m€1.9m€2.0m€2.3m▲ 16.9%
Line20202022202320242025Change
Profit (loss) for the period9904€4.1m€5.0m€4.5m€6.5m€9.0m▲ 37.7%
+ Depreciation and write-downs630€0.06m€0.05m€0.04m€0.03m€0.02m▼ 19.9%
Operating cash flow (approximation)€4.2m€5.1m€4.5m€6.6m€9.0m▲ 37.4%
Investment in fixed assets (approximation)---€0.02m-€0.005m-€0.006m▼ 37.9%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 34 filings with the National Bank
Financial year Type Filed Reference
30-06-2025 full format 19-12-2025 2025-00585921
30-06-2024 full format 18-12-2024 2024-00618674
30-06-2023 full format 20-11-2023 2023-00513284
30-06-2022 full format 15-12-2022 2022-20537723
30-06-2021 full format 20-12-2021 2021-80800234
30-06-2020 full format 18-12-2020 2020-76100601
30-06-2019 full format 27-12-2019 2019-77600195
30-06-2018 full format 14-03-2019 2019-06900515
30-06-2017 full format 30-01-2018 2018-02600588
30-06-2016 full format 09-02-2017 2017-04100240

Show all 34 filings

Similar companies · same sector, comparable size

Of the 1,866 active companies whose main activity is wholesale of pharmaceutical and medical goods (NACE 46460), figures are known for 1,123. 193 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts

10 awards · 2025 to 2026
Immunoglobuline humaine normale pour administration intraveineuse: PHARM-2026-845 - 1
buyer: Cliniques universitaires Saint LucMedical equipment and pharmaceuticalsawarded 07-10-2026€16.3m2 tendersTED 731370-2026
Raamovereenkomst voor de aankoop van IV Immunoglobulinen en Protrombine complex concentraat: IV Immunoglobulinen (90% deel)
buyer: VZW Maria MiddelaresMedical equipment and pharmaceuticalsawarded 22-09-2026€19.3m3 tendersTED 658439-2026
Raamovereenkomst voor het leveren van immunoglobulines IV 10%
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 21-09-2026€27.3m3 tendersTED 659219-2026
Aankoop en levering van plasmaderivaten: Intraveneuze immunoglobulinen 100mg/ml
buyer: Algemeen Ziekenhuis Sint-Maria vzwMedical equipment and pharmaceuticalsawarded 09-09-2026€10.5m3 tendersTED 634542-2026
Immunoglobulinen voor intraveneuze toediening (IVIG)
buyer: VITAZ vzwMedical equipment and pharmaceuticalsawarded 31-08-2026€6.9m3 tendersTED 608475-2026
Show 5 more contracts
RO voor het leveren van Humane Immunoglobulinen voor Intraveneuze Toediening - 2026: Raamovereenkomst voor het leveren van Humane Immunoglobulinen voor Intraveneuze Toediening - 2026
buyer: AZ Sint-Jan Brugge AVMedical equipment and pharmaceuticalsawarded 13-07-2026€10.1m4 tendersTED 494556-2026
Intraveneuze immunoglobulinen
buyer: AZ Delta vzwMedical equipment and pharmaceuticalsawarded 18-05-2026€9.7m3 tendersTED 350002-2026
Accord-Cadre pour le traitement de plasma fourni par les établissements de transfusion sanguine agrées par le ministre compétent en Belgique et la garantie aux hôpitaux d'une offre suffisante en dérivés plasmatiques stables (solutions d'albumine et immunoglobulines pour administration intravenineuse) fabriqués à partir du plasma fourni: FODVVVL/Plasmaderivaten/2025/001bis - 1
buyer: SPF Santé Publique Sécurité de la Chaîne Alimentaire et EnvironnementMedical equipment and pharmaceuticalsawarded 01-12-2025€434.6m1 tenderTED 858762-2025
Accord-cadre pour le traitement de plasma fourni par les établissements de transfusion sanguine agrées par le ministre compétent en Belgique et la garantie aux hôpitaux d’une offre suffisante en dérivés plasmatiques stables (solutions d’albumine et immunoglobulines pour administration intraveineuse) fabriqués à partir du plasma fourni: PLASMADERIVATEN/2025/001 - 1
buyer: FOD Volksgezondheid Veiligheid van de Voedselketen en LeefmilieuMedical equipment and pharmaceuticalsawarded 21-08-2025€371.1m1 tenderTED 551621-2025
Raamovereenkomst voor het leveren van polyvalente immunoglobulinen voor subcutane toediening
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 16-05-2025€10.7m2 tendersTED 485586-2025

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.

Directors

Directors
2 directors, last change in 2026

Board 2

Camilla Shen
Director · since 01-10-2024
Current
Alexandros Sigalas
Director · since 30-03-2026
Current

Statutory auditor 1

DELOITTE Bedrijfsrevisoren BV
Statutory auditor · since 02-06-2025 · permanent representative: Pieter-Jan Van Durme
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
16 of this company's 18 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.

Mandate history

5 people since 2024, 3 in office
Show
  • Board
  • Statutory auditor
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Camilla Shen
  • Director, from 01-10-2024 to date
Alexandros Sigalas
  • Director, from 30-03-2026 to date
DELOITTE Bedrijfsrevisoren BV
  • Statutory auditor, from 02-06-2025 to date
Marcelo Estrella
  • Director, from before 02-06-2025 to 30-03-2026
Lutz Bonacker
  • Director, until 30-09-2024
See the board, name and registered office on a given date →

Owners and capital

Owners

4 owners

Chain of control

  1. CSL LimitedAU consolidates
  2. CSL Behring ApSDK 51.83%
  3. CSL BEHRING

Highest known parent: CSL Limited (Australia). The sources do not say who stands above it.

Owners 4

According to the annual accounts to 30-06-2025 of CSL BEHRING and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Group and network

Holdings and subsidiaries

1 holding

Holdings 1

According to the annual accounts to 30-06-2025 of CSL BEHRING and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Connections & network

2 current directors
Depth

The network starts from this company’s directors. Other companies they run appear here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

History

On 15 February 1995, CSL BEHRING was incorporated.1 Turnover went from €124.6m in 2020 to €184.4m in 2025 and headcount from 30.3 to 36.4 full-time equivalents.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2020 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-01-2027
2026
07-07
Gazette deed Resignation: Marcelo Estrella (director)
Appointment: Alexandros Sigalas (director) · Director discharge4 facts ▸
  • General meeting, 29-03-2026
  • Director resignation, Marcelo Estrella (director)
  • Director discharge, Marcelo Estrella (director)
  • Director appointment, Alexandros Sigalas (director)
2025
19-12
NBB filing Annual accounts filed
financial year 2025 · full format
30-06
Financial Highest result from 2020 to 2025net €9.0m ▲37.7%
Operating result €12.2m, net result €9.0m, both a record.
02-06
Gazette deed Reappointment: Marcelo Estrella (director)
Resignations: Lutz Bonacker (director) and EY Bedrijfsrevisoren BV (statutory auditor) · Appointments: Camilla Shen (director) and Deloitte Bedrijfsrevisoren BV (statutory auditor)7 facts ▸
  • General meeting, 28-11-2024
  • Director reappointment, Marcelo Estrella (director)
  • Director resignation, Lutz Bonacker (director)
  • Director appointment, Camilla Shen (director)
  • Auditor resignation, EY Bedrijfsrevisoren BV (statutory auditor)
  • Auditor appointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
  • Other provision, “materiële vergissing in notulen algemene vergadering vorig jaar, benoeming Deloitte Bedrijfsrevisoren BV niet opgenomen in notulen” (deed in Dutch)
2024
18-12
NBB filing Annual accounts filed
financial year 2024 · full format
2023
20-11
NBB filing Annual accounts filed
financial year 2023 · full format
2022
15-12
NBB filing Annual accounts filed
financial year 2022 · full format
30-06
Financial Equity above €25mequity €28.3m ▲52.9%
A profit in every financial year since 2020 builds equity to €28.3m.
2021
20-12
NBB filing Annual accounts filed
financial year 2021 · full format
2020
18-12
NBB filing Annual accounts filed
financial year 2020 · full format
2019
27-12
NBB filing Annual accounts filed
financial year 2019 · full format
14-03
NBB filing Annual accounts filed
financial year 2018 · full format · 42 days late
2018
30-01
NBB filing Annual accounts filed
financial year 2017 · full format
2017
09-02
NBB filing Annual accounts filed
financial year 2016 · full format · 9 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 34 annual accounts filed, the latest 10 are here; all 34 are under Financials.
2 of 18 deeds read
About the unread acts

Of the 18 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 16 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPublic limited company
Founded15-02-1995
Financial year end30-06
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
E-invoicing
Reachable via Peppol
Peppol ID 0208:0454483701
Also 9925:BE0454483701
Registered 13-12-2023

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 27 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Mechelen · 1 establishment unit since 1995
registered office establishment The establishment unit on the map
Ground area
1.1 ha
Building footprint
3,812 m²
Building volume
60,373 m³
Parcel 12403E0765/00L000, Flanders · tallest building 18.8 m. Linked by address, not a title deed.
1 establishment unit
Bedrijvenlaan 11, 2800 Mechelen
Wholesale of pharmaceutical and medical goods
since 1995unit no. 2.071.269.902
1 parcel
Flanders 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
12403E0765/00L000 Flanders 1.1 ha 1 · 3,812 m² 18.8 m · 6
How the parcels are linked
Good to know
The parcel matches the address exactly.

Articles of association

Other provisionsOther rules from the articles that fall under none of the themes above.
1 more provision in the deed, see the deed of 02-06-2025

Read from the deeds: 1 provision, deed of 02-06-2025